How to Get Reclast (Zoledronic Acid) in Oregon

What Is Zoledronic Acid and Why Is It Prescribed?

Zoledronic acid is a potent intravenous bisphosphonate that inhibits osteoclast-mediated bone resorption. A single 5 mg infusion provides 12 months of skeletal protection, making it the least frequent dosing schedule among all osteoporosis therapies approved by the FDA.

The drug earned its initial FDA approval in 2007 based on the HORIZON Key Fracture Trial (HORIZON-PFT), a randomized, double-blind study enrolling 7,765 postmenopausal women with osteoporosis. Over three years, zoledronic acid reduced the risk of morphometric vertebral fractures by 70% (3.3% vs. 10.9% with placebo; relative risk 0.30, 95% CI 0.24 to 0.38) and hip fractures by 41% (1.4% vs. 2.5%; hazard ratio 0.59) 1. These results established once-yearly IV zoledronic acid as a first-line option for patients at high fracture risk or those unable to tolerate oral bisphosphonates.

The Endocrine Society's 2019 clinical practice guideline recommends bisphosphonates, including zoledronic acid, as initial pharmacologic therapy for postmenopausal women at high risk of fracture 2. Zoledronic acid is particularly useful for patients who experience gastrointestinal side effects from oral alendronate or risedronate, who have difficulty remaining upright for 30 minutes after dosing, or who simply prefer a once-yearly treatment over weekly or monthly pills.

Oregon Prescribing: Who Can Write the Prescription?

Any Oregon-licensed prescriber with authority to order injectable medications can prescribe zoledronic acid. That includes physicians (MD/DO), nurse practitioners, and physician assistants.

Oregon grants full practice authority to nurse practitioners under ORS 678.375, meaning NPs can independently evaluate a patient, order a DXA scan, review labs, and prescribe zoledronic acid without physician oversight 3. Physician assistants practice under a collaborative agreement with a supervising physician but retain prescriptive authority for Schedule II through V drugs and non-scheduled medications alike. For a once-yearly infusion drug with no abuse potential, the prescribing pathway is straightforward regardless of provider type.

If you already have an osteoporosis diagnosis and a recent DXA scan from another state, an Oregon provider can review your records and write the prescription without repeating the scan. Oregon does not impose state-specific prescribing restrictions on bisphosphonates beyond standard DEA and Board of Pharmacy rules 4.

Telehealth Access in Oregon

Oregon permits telehealth prescribing for zoledronic acid. A provider licensed in Oregon can conduct a video or audio visit, review your imaging and lab results, and transmit the prescription electronically to a pharmacy or infusion center.

Oregon's telehealth parity law (ORS 743A.058) requires commercial insurers to cover telehealth services at the same rate as in-person visits. Oregon Health Plan (Medicaid) also covers telehealth encounters for specialist consultations, including endocrinology and rheumatology visits where osteoporosis management is discussed 5. The practical benefit is significant: patients in rural counties like Harney, Lake, or Malheur can consult with a bone health specialist in Portland or Eugene without a multi-hour drive.

A telehealth visit for zoledronic acid typically involves reviewing a DXA scan (T-score of <-2.5 at the lumbar spine or femoral neck, or <-1.0 with a prior fragility fracture), confirming that pre-infusion labs are within acceptable range, and then sending the order to a local infusion site. The infusion itself must occur in person, as the drug is administered intravenously.

Required Labs Before Infusion

Zoledronic acid is contraindicated in patients with hypocalcemia, and renal impairment increases the risk of adverse events. Pre-infusion laboratory testing is not optional.

The FDA prescribing information for Reclast specifies that serum creatinine must be measured before each dose, and the drug is contraindicated in patients with creatinine clearance <35 mL/min 6. The American Association of Clinical Endocrinology (AACE) 2020 guideline further recommends checking serum calcium and 25-hydroxyvitamin D before infusion, correcting any deficiency before administering the drug 7.

Here is the standard pre-infusion lab panel:

• Serum creatinine with estimated GFR: Must confirm eGFR ≥35 mL/min/1.73 m². If borderline, a 24-hour creatinine clearance may be ordered.
• Serum calcium (corrected for albumin): Must be within normal range. Hypocalcemia requires correction with calcium and vitamin D supplementation before scheduling the infusion.
• 25-hydroxyvitamin D: Levels below 20 ng/mL should be repleted. Many clinicians target 30 to 50 ng/mL before infusion.
• Complete blood count: Not universally required, but some infusion centers request it.
• Phosphorus and magnesium: Checked at some centers, particularly for patients on proton pump inhibitors or diuretics.

Labs can be drawn at any Oregon laboratory (Quest, LabCorp, OHSU, Providence, or hospital-based labs) and results shared with your prescriber electronically. Most providers want labs completed within 30 days of the scheduled infusion.

Prior Authorization Under Oregon Medicaid

Oregon Medicaid (Oregon Health Plan) covers zoledronic acid for osteoporosis with prior authorization. The PA process confirms medical necessity before the state pays for the drug and its administration.

Documentation typically required for PA includes a DXA scan showing a T-score of <-2.5 at the spine or hip (or <-1.0 with a fragility fracture history), evidence that the patient has tried or cannot tolerate oral bisphosphonate therapy, and recent lab results confirming adequate renal function 8. Some Oregon coordinated care organizations (CCOs) may also ask for documentation of falls risk assessment or FRAX score.

Commercial insurers in Oregon, including Providence Health Plan, Moda, PacificSource, and Regence, generally cover brand-name Reclast and generic zoledronic acid on their specialty pharmacy tiers. Prior authorization requirements vary by plan. Generic zoledronic acid typically faces fewer PA hurdles than brand-name Reclast due to cost. The average wholesale price for generic zoledronic acid 5 mg/100 mL is roughly $300 to $500 per infusion, compared to over $1,100 for brand-name Reclast 9.

A 2017 analysis in Osteoporosis International found that among Medicare beneficiaries prescribed zoledronic acid, approximately 28% experienced a treatment delay of more than 60 days due to insurance or logistical barriers 9. Starting the PA process early (ideally at the time labs are ordered) can prevent similar delays for Oregon patients.

Where to Get the Infusion in Oregon

Zoledronic acid is administered as a 15-minute intravenous infusion in a clinical setting. You cannot self-administer this drug at home. Oregon offers several types of infusion sites.

Hospital-based infusion centers at OHSU, Providence Portland, Providence St. Vincent, Legacy Emanuel, PeaceHealth Sacred Heart (Eugene), and Asante Rogue Regional (Medford) all administer zoledronic acid. These centers handle insurance billing directly and typically have the drug in stock.

Freestanding infusion clinics operate in the Portland metro area, Salem, Bend, and Eugene. These outpatient facilities often offer shorter wait times and more flexible scheduling than hospital centers.

Physician office infusion suites are available at some endocrinology and rheumatology practices. If your prescribing provider has an in-office infusion suite, the entire visit (evaluation, labs review, infusion) can happen in a single appointment.

Home infusion services are limited for zoledronic acid because of the need for IV access and monitoring for post-infusion reactions, including fever, myalgia, and arthralgia, which occur in approximately 32% of patients after their first dose according to the HORIZON-PFT data 1. Most payers and providers prefer a supervised clinical setting.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center in Portland, has noted: "Zoledronic acid remains one of the most effective and underused osteoporosis treatments. The once-yearly dosing eliminates adherence concerns that plague daily and weekly oral therapies" 10.

503A Compounding Pharmacies in Oregon

Oregon licenses 503A compounding pharmacies under the Oregon Board of Pharmacy. These pharmacies can compound patient-specific preparations, including zoledronic acid for IV infusion, when a valid prescription is provided.

A 503A pharmacy compounds medications pursuant to individual prescriptions, unlike 503B outsourcing facilities that produce larger batches without patient-specific prescriptions. In Oregon, 503A pharmacies must comply with USP <797> sterile compounding standards, which the Board of Pharmacy enforces through regular inspections 11. For an IV bisphosphonate like zoledronic acid, sterile technique is non-negotiable.

Compounded zoledronic acid may cost less than the commercially manufactured product, though insurance coverage for compounded drugs is inconsistent. Patients paying out of pocket should request a quote from both a specialty pharmacy (for the FDA-approved generic) and a 503A compounder before deciding. Oregon 503A pharmacies can ship within the state but cannot ship across state lines under federal law.

Transferring a Prescription to Oregon

If you are moving to Oregon or splitting time between states, you can transfer an existing zoledronic acid prescription. Oregon Board of Pharmacy rules permit prescription transfers between pharmacies, including interstate transfers.

The practical steps are simple. Contact your current pharmacy and ask them to transfer the prescription to an Oregon pharmacy. Alternatively, your prescriber can send a new prescription to an Oregon-based infusion center or specialty pharmacy. Because zoledronic acid is dosed once yearly, the timing of your move relative to your last infusion matters. If you received your most recent infusion within the past 10 to 11 months, you can establish care with an Oregon provider and schedule the next infusion locally before the 12-month mark.

For patients transferring from a state where telehealth was used for the initial prescription, the Oregon provider will likely want to review your full medical record, including DXA scans, prior infusion records, and lab trends, before assuming ongoing management 12.

Timeline: From First Visit to Infusion

The process from initial consultation to receiving the infusion typically takes 2 to 6 weeks in Oregon, depending on insurance type and lab turnaround.

Week 1: Initial consultation (in-person or telehealth). Provider reviews DXA scan, orders pre-infusion labs if not already completed.

Week 1 to 2: Labs drawn and results returned. Vitamin D repletion initiated if levels are low (this can add 4 to 8 weeks if severe deficiency requires high-dose ergocalciferol or cholecalciferol loading).

Week 2 to 3: Prior authorization submitted (if required). Commercial plans often respond within 5 to 7 business days. Oregon Medicaid CCOs may take up to 14 days.

Week 3 to 5: Infusion scheduled. Availability at hospital-based centers may require 1 to 2 weeks of lead time; freestanding clinics sometimes offer same-week appointments.

Day of infusion: The entire appointment takes 30 to 45 minutes. The infusion itself is 15 minutes minimum. Patients are monitored briefly afterward and advised to stay well hydrated for 48 hours. Acetaminophen before and after the infusion can reduce the acute-phase reaction (fever, muscle aches) that affects roughly one-third of first-time recipients 1.

Safety Considerations Specific to Oregon Patients

Two rare but serious adverse effects of zoledronic acid deserve mention: osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).

The incidence of ONJ with yearly zoledronic acid for osteoporosis is estimated at 1 in 10,000 to 1 in 100,000 patient-years, far lower than the rates seen with higher-dose oncology regimens 13. The American Dental Association recommends a dental examination before starting bisphosphonate therapy but states that routine dental care should not be delayed because of bisphosphonate use 14. Oregon patients should inform their dentist that they are receiving zoledronic acid, especially before planned extractions or implant surgery.

Atypical femoral fractures are associated with prolonged bisphosphonate use, typically beyond 5 years. A 2020 meta-analysis published in the Journal of Bone and Mineral Research calculated the absolute risk of AFF at 3.0 to 5.0 per 10,000 patient-years of bisphosphonate exposure, compared to a spontaneous AFF rate of approximately 0.5 per 10,000 patient-years in untreated populations 15. The Endocrine Society recommends considering a bisphosphonate holiday after 3 to 6 years of zoledronic acid therapy in patients whose fracture risk has stabilized 2.

Post-infusion hydration is especially relevant for Oregon patients receiving their infusion during summer months. Adequate fluid intake (at least 2 glasses of water before the infusion and continued hydration afterward) protects renal function and reduces the severity of acute-phase symptoms.

The HORIZON Recurrent Fracture Trial, a companion study to HORIZON-PFT, demonstrated that zoledronic acid given within 90 days of surgical repair of a hip fracture reduced the risk of new clinical fractures by 35% and reduced all-cause mortality by 28% (p = 0.01) 16. Dr. Dennis Black, professor of epidemiology at UCSF and co-investigator of the HORIZON trials, stated: "The mortality reduction was unexpected and remains one of the most striking findings in osteoporosis treatment research" 16.